Bausch & Lomb Corp (BLCO) Form 10-Q — Jul 29, 2026
For the six months ended June 30, 2026, Bausch + Lomb reported revenues of $2.638 billion, an increase from $2.415 billion in the prior year period. Segment information indicates growth in the Vision Care and Pharmaceuticals segments, with Vision Care revenues reaching $1.495 billion and Pharmaceutical revenues reaching $659 million. The company significantly narrowed its net loss attributable to Bausch + Lomb Corporation to $85 million, or $0.24 per share, compared to a net loss of $274 million, or $0.78 per share, in the same period of 2025. Restructuring, integration, and separation costs decreased to $12 million from $32 million in the prior year period.
Key figures
- Revenue
- 2638
- Total Debt
- 5077
- Cash Position
- 367
- Revenue prior year
- 2415
- Shares outstanding
- 357165246
Price after filing
Close on the filing date to close N calendar days later (from $16.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.